Ion Channel Screening ServicesMedicinal chemists and toxicologists using AVIVA's in vitro hERG (kV11.1) electrophysiology assay, calcium channel CaV1.2 and the sodium channel Nav1.5 assay can efficiently test compounds for potential cardiac liability. AVIVA's reliable, accurate cardiac profiling of compounds meets the critical needs of pharmaceutical and biotech companies with small molecule therapeutic programs. AVIVA's ion channel screening assay can rapidly support medicinal chemistry programs by testing hundreds of molecules per week.
Our cardiac safety panel which includes hERG, NaV1.5 and CaV1.2 offers convenience of multiple channels for rigorous safety analysis, and savings as a bundled service. Our ion channel assay provides comprehensive inhibition data and IC50 metrics.
AVIVA offers flexible solutions for ion channel drug discovery. AVIVA's ion channel screening services are highly customizable to suit your project and therapeutic safety study. We modify our services based on needs of the client in these parameters::
Number of Concentrations
We offer the screening services on the following ion channels:
|hERG (kV11.1)||hNav1.7 (Cardiac)|
Don’t see the ion channel you’re looking for? We also can work with customer's cell lines- providing validation and compound screening data.
Ready to get started? Click here to contact AVIVA's scientific team and mention our Summer 2016 Discount for new customers!
Even more information:
For an introduction to compound screening click here to learn about the importance of hERG screening and cardiovascular safety.
Concerned about the FDA's new development recommendations, known as CiPA? Click here to learn how these changes might affect your ion channel screening work flow.